These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 34334893)
1. Effectiveness of ChAdOx1 nCOV-19 Vaccine: Experience of a tertiary care institute. Bobdey S; Kaushik SK; Sahu R; Naithani N; Vaidya R; Sharma M; Vashishtha K; Yadav AK; Sen S; Karade S Med J Armed Forces India; 2021 Jul; 77(Suppl 2):S271-S277. PubMed ID: 34334893 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis. Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK; Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183 [TBL] [Abstract][Full Text] [Related]
4. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population. Theresa Pool SN; Shroff EH; Chetty A; Lewis L; Nonhlanhla YZ; Abdool Karim SS PLoS One; 2024; 19(4):e0299747. PubMed ID: 38578809 [TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Hall VJ; Foulkes S; Saei A; Andrews N; Oguti B; Charlett A; Wellington E; Stowe J; Gillson N; Atti A; Islam J; Karagiannis I; Munro K; Khawam J; Chand MA; Brown CS; Ramsay M; Lopez-Bernal J; Hopkins S; Lancet; 2021 May; 397(10286):1725-1735. PubMed ID: 33901423 [TBL] [Abstract][Full Text] [Related]
7. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Singanayagam A; Hakki S; Dunning J; Madon KJ; Crone MA; Koycheva A; Derqui-Fernandez N; Barnett JL; Whitfield MG; Varro R; Charlett A; Kundu R; Fenn J; Cutajar J; Quinn V; Conibear E; Barclay W; Freemont PS; Taylor GP; Ahmad S; Zambon M; Ferguson NM; Lalvani A; Lancet Infect Dis; 2022 Feb; 22(2):183-195. PubMed ID: 34756186 [TBL] [Abstract][Full Text] [Related]
8. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Menni C; Klaser K; May A; Polidori L; Capdevila J; Louca P; Sudre CH; Nguyen LH; Drew DA; Merino J; Hu C; Selvachandran S; Antonelli M; Murray B; Canas LS; Molteni E; Graham MS; Modat M; Joshi AD; Mangino M; Hammers A; Goodman AL; Chan AT; Wolf J; Steves CJ; Valdes AM; Ourselin S; Spector TD Lancet Infect Dis; 2021 Jul; 21(7):939-949. PubMed ID: 33930320 [TBL] [Abstract][Full Text] [Related]
9. Safety, immunogenicity & effectiveness of the COVID-19 vaccine among healthcare workers in a tertiary care hospital. Kataria S; Sharma P; Singh MK; Deswal V; Kumar K; Alam S; Gupta V; Phogat R; Sarma S; Patil N; Dutt R; Singh P; Saxena R; Trehan N Indian J Med Res; 2022; 155(5&6):518-525. PubMed ID: 36348600 [TBL] [Abstract][Full Text] [Related]
10. Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India. Kaur U; Fatima Z; Maheshwari K; Sahni V; Dehade A; Kl A; Yadav AK; Kansal S; Jaisawal V; Chakrabarti SS Drug Saf; 2023 Jun; 46(6):553-563. PubMed ID: 37133805 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. Nordström P; Ballin M; Nordström A Lancet Reg Health Eur; 2021 Dec; 11():100249. PubMed ID: 34693387 [TBL] [Abstract][Full Text] [Related]
12. Vaccine effectiveness to protect against moderate or severe disease in COVID cases: A prospective cohort study. Joshi RK; Muralidharan CG; Ahuja A; Mukherjee R; Chaurasia S; Manjaly L; Divyanshi ; Sahoo AK; Gosavi J; Thomas A Med J Armed Forces India; 2022 Apr; 79(Suppl 1):S102-11. PubMed ID: 35400799 [TBL] [Abstract][Full Text] [Related]
13. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Nordström P; Ballin M; Nordström A Lancet; 2022 Feb; 399(10327):814-823. PubMed ID: 35131043 [TBL] [Abstract][Full Text] [Related]
14. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ; Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Hyams C; Marlow R; Maseko Z; King J; Ward L; Fox K; Heath R; Tuner A; Friedrich Z; Morrison L; Ruffino G; Antico R; Adegbite D; Szasz-Benczur Z; Garcia Gonzalez M; Oliver J; Danon L; Finn A Lancet Infect Dis; 2021 Nov; 21(11):1539-1548. PubMed ID: 34174190 [TBL] [Abstract][Full Text] [Related]
16. Surveillance on Adverse Events Following COVISHIELD (ChAdOx1 nCoV-19) vaccination in Goa, India: An Observational Study. Jose D; Dhupdale N; Cacodcar JA; Kamat U Curr Drug Saf; 2023; 18(4):516-527. PubMed ID: 35927820 [TBL] [Abstract][Full Text] [Related]
17. Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial). Muadchimkaew M; Siripongboonsitti T; Wongpatcharawarakul S; Boonsankaew C; Tawinprai K; Soonklang K; Mahanonda N Int J Infect Dis; 2022 Nov; 124():190-198. PubMed ID: 36180032 [TBL] [Abstract][Full Text] [Related]
18. Pneumonia Frequency and Severity in Patients With Symptomatic COVID-19: Impact of mRNA and Adenovirus Vector Vaccines. Vicini S; Bellini D; Iannarelli A; Rengo M; Pelle G; Ruggiero S; Fusco M; Ambrogi C; Carbone I AJR Am J Roentgenol; 2022 Nov; 219(5):752-761. PubMed ID: 35642761 [No Abstract] [Full Text] [Related]
19. Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records. Horne EMF; Hulme WJ; Keogh RH; Palmer TM; Williamson EJ; Parker EPK; Green A; Walker V; Walker AJ; Curtis H; Fisher L; MacKenna B; Croker R; Hopcroft L; Park RY; Massey J; Morley J; Mehrkar A; Bacon S; Evans D; Inglesby P; Morton CE; Hickman G; Davy S; Ward T; Dillingham I; Goldacre B; Hernán MA; Sterne JAC BMJ; 2022 Jul; 378():e071249. PubMed ID: 35858698 [TBL] [Abstract][Full Text] [Related]
20. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. Katikireddi SV; Cerqueira-Silva T; Vasileiou E; Robertson C; Amele S; Pan J; Taylor B; Boaventura V; Werneck GL; Flores-Ortiz R; Agrawal U; Docherty AB; McCowan C; McMenamin J; Moore E; Ritchie LD; Rudan I; Shah SA; Shi T; Simpson CR; Barreto ML; Oliveira VA; Barral-Netto M; Sheikh A Lancet; 2022 Jan; 399(10319):25-35. PubMed ID: 34942103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]